Inequality and Human Genetics
By Richard Hayes,
The New York Times
| 09. 16. 2008
[Letter to the editor]
David Frum correctly acknowledges that income inequality in the United States has been growing steadily and that the use of genetic technology by the affluent to enhance the "intelligence, health, beauty and strength" of their offspring would exacerbate this trend. But his suggestion that this challenge could be addressed by somehow ensuring that all have access to such technology is woefully misguided. The advent of these technologies would spark a techno-eugenic rat race impossible to constrain absent some system of authoritarian, allocative control. It would fundamentally change the way people regard their children and one another and undermine the integrity of the common human nature that sustains all human values, beliefs and institutions. The genetic modification of our children is a practice that conservatives and liberals alike should be able to agree poses far more risks than benefits, and should be taken off the table as an option.
Richard Hayes
Executive Director
Center for Genetics and Society
Oakland, Calif.
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...